GRAZAX® is the world's first registered tablet-based allergy vaccine, and the first allergy tablet to treat the underlying cause of allergy as well as the symptoms.
Clinical trials document that the effect of GRAZAX® persists following completion of the recommended three-year treatment regimen.
ALK is the first company ever to document a persistent disease modifying vaccination effect of a tablet-based allergy vaccine. Patients cannot obtain such a persistent vaccination effect with symptom-relieving allergy medication.